Can a new drug tame hepatitis e? a first human trial begins
NCT ID NCT07728487
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called AT-587 in healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for hepatitis E, a liver infection that currently has no approved therapy. Participants receive either AT-587 or a placebo, and researchers monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called AT-587
- What this could lead to
- If safe and effective, AT-587 could become a treatment option for hepatitis E, a liver infection with no approved therapy.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, so it does not yet test whether the drug works against the virus. Side effects may emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS E are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atea Study Site
RECRUITINGEdegem, 2650, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.